Takara Bio, MolMed Announce That Phase I/II Clinical Trial of HSV-TK Gene Therapy Delivers Positive Results.Tokyo, Japan, Dec 15, 2005 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Takara Bio announced on December 13 that its Italian research partner MolMed has presented the results of phase I and II clinical trials of HSV-TK gene therapy, which targets hematopoietic hematopoietic /he·ma·to·poi·et·ic/ (-poi-et´ik) 1. pertaining to hematopoiesis. 2. an agent that promotes hematopoiesis. hematopoietic 1. pertaining to or affecting the formation of blood cells. malignancies, at the 47th Annual Meeting of the American Society of Hematology held in Atlanta. The clinical trials have confirmed that the HSV-TK gene therapy was superior to conventional treatments in the primary endpoints, especially in survival rates. Now that it has attained the positive results, MolMed will begin a phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA randomized ran·dom·ize tr.v. ran·dom·ized, ran·dom·iz·ing, ran·dom·iz·es To make random in arrangement, especially in order to control the variables in an experiment. multicenter trial in Europe within 2006. Takara Bio and MolMed have signed a licensing agreement whereby Takara Bio can exclusively commercialize MolMed's HSV-TK gene therapy in Asia and MolMed retains nonexclusive licenses for Takara's RetroNectin technology in Europe and the US. Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion